Greenville man called his mom screaming after $250,000 win
RALEIGH, N.C. (WNCT) — David Harvard of Greenville wanted to immediately tell someone after a $5 scratch-off turned into a $250,000 top prize.
'I called my mom first screaming that I won,' Harvard said. Harvard bought his lucky 20X The Cash scratch-off from the Speedway on W. Fire Tower Road in Winterville. 'It's really a blessing,' Harvard said.
Harvard said his prize at lottery headquarters Friday and after required state and federal tax withholdings, took home $179,376.
The 20X The Cash game debuted in February 2024 with 10 $250,000 top prizes. One $250,000 prize remains to be claimed.
For details on how $10.3 million raised by the lottery made a difference for education programs in Pitt County last year, visit www.nclottery.com
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 minutes ago
- Associated Press
Chilco River Holdings Announces Letter of Intent for Strategic Acquisition of Excuse Wine & Spirits, Inc.
Chatsworth, California--(Newsfile Corp. - June 12, 2025) - Chilco River Holdings, Inc. (OTC Pink: CRVH) ('Chilco' or the 'Company'), a dynamic holding company and diversified business accelerator, is pleased to announce the signing of a Letter of Intent ('LOI') to acquire a majority equity interest in Excuse Wine & Spirits, Inc. ('Excuse') in an all-stock transaction. Excuse Wine & Spirits, Inc. is a privately held company that owns a portfolio of proprietary trademarks, intellectual property, and high-quality assets in the alcoholic beverage sector, with a particular focus on tequila and bourbon. Over the past two years, the company has successfully soft launched a range of innovative products, garnering strong consumer response through targeted market testing in several high-growth metropolitan regions across the United States. Excuse is currently in advanced negotiations with national and regional distribution partners to support a nationwide rollout of its product lines. Strategic Growth Platform Upon completion of the proposed transaction, Excuse will operate as a majority-owned subsidiary of Chilco River Holdings. Under Chilco's leadership, Excuse will benefit from strategic oversight, operational resources, and access to growth capital, enabling the brand to accelerate its market presence, scale operations, and enhance overall brand equity. This acquisition aligns with Chilco River's mission to build a diversified portfolio of high-growth consumer brands in the alcoholic beverage industry. The company continues to explore additional acquisition opportunities in adjacent sectors and emerging global markets as part of its long-term growth strategy. Forward Momentum The LOI reflects a mutual intention by both parties to proceed in good faith toward the negotiation and execution of a definitive agreement which is expected to close before the end of the month. The LOI highlights a shared commitment to collaboration and long-term value creation for shareholders. Chilco River Holdings is also receiving significant inbound interest from other acquisition targets in high-growth, in-demand sectors. The company remains committed to keeping its shareholders informed and will provide timely updates on all material developments as they occur. About Chilco River Holdings, Inc. Chilco River Holdings, Inc. is a strategic holding company and business accelerator focused on building long-term value through the acquisition, development, and growth of diversified businesses. With a core emphasis on the premium alcoholic beverage sector, Chilco River specializes in high-quality spirits and innovative ready-to-drink (RTD) products. The Company leverages operational expertise, brand development capabilities, and strategic partnerships to drive sustainable growth across its portfolio. For media or investor inquiries, please contact: Investor Relations Chilco River Holdings, Inc. Email: [email protected] Website: To view the source version of this press release, please visit
Business Wire
12 minutes ago
- Business Wire
MFA Financial, Inc. Announces Dividend of $0.36 per Share
NEW YORK--(BUSINESS WIRE)--MFA Financial, Inc. (NYSE: MFA) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.36 per share of common stock. The dividend will be paid on July 31, 2025, to common stockholders of record on June 30, 2025. MFA Financial, Inc. is a leading specialty finance company that invests in residential mortgage loans, residential mortgage-backed securities and other real estate assets. Through its wholly-owned subsidiary Lima One Capital, MFA also originates and services business purpose loans for real estate investors. MFA has distributed over $4.9 billion in dividends to stockholders since its initial public offering in 1998. MFA is an internally managed, publicly-traded real estate investment trust. Category: Dividend
Associated Press
13 minutes ago
- Associated Press
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', 'NRx' or the 'Company'), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ('HOPE,' or the 'Company'), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals and Co-CEO of HOPE, will deliver a corporate presentation highlighting the company's latest advances. The presentation will be available on demand to registered attendees beginning at 7:00 a.m. Eastern Time on Monday, June 16, 2025. In addition, the company will be participating in one-on-one meetings with investors throughout the conference. Please request 1:1 meetings on the HCW conference website listed below. Event Details: About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential as a treatment for complicated UTI. NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative free IV ketamine) for use in ketamine's currently approved indications. Additionally, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. ( ), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, whether the USPTO approves the Company's patent, and whether the FDA will approve the Company's NDA. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
